Cabolin Tablet
Cabergoline
1mg
Renata PLC.
| Pack size | 4's Pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 150.00 AED |
Available as:
Indications
Cabolin Tablet is used for:
Prevention of lactation, Lactation suppression, soon after childbirth, stillbirth, abortion or miscarriage, hyperprolactinemia, prolactinomas, parkinson's disease, uterine fibroids, acromegaly, cushing's disease, pituitary adenomas
Adult Dose
Oral
Prevent milk production (lactation)
Adult: 1 mg (two 0.5 mg tablets) as a single dose on the 1st day postpartum.
Suppression of lactation
Adult: 250 mcg (one half of 0.5 mg tablet) every 12 hr for 2 days.
Hyperprolactinemia-associated disorders (To reduce prolactin levels in other conditions)
Adult: Initially take one 0.5 mg tablet (to be taken in two doses) spread out over a week (e.g. half a tablet on Monday and the other half of the tablet on Thursday).
Dose will be increased up to a maximum dose of 4.5 mg or until have responded fully to treatment.
As monotherapy in Parkinson's disease; Adjunct to levodopa treatment in Parkinson's disease
Adult: Initially, 0.5 mg daily in monotherapy and 1 mg daily as adjunct, may increase in increments of 0.5-1 mg at 7- or 14-day intervals. Max: 3 mg daily.
Hyperprolactinemia
Indicated for hyperprolactinemic disorders of either idiopathic or pituitary adenoma origin
The recommended dosage of Cabergoline Tablets for initiation of therapy is 0.25 mg twice a week.
The dosage may be increased by 0.25 mg twice weekly up to a dosage of 1mg twice a week according to the patient's serum prolactin level.
Dosage increases should not occur more rapidly than every 4 weeks so that the physician can assess the patient's response to each dosage level.
If the patient does not respond adequately and no additional benefit is observed with higher doses, the lowest dose that achieved maximal response should be used and other therapeutic approaches considered.
After a normal serum prolactin level has been maintained for 6 months, Cabergoline may be discontinued, with periodic monitoring of the serum prolactin level to determine whether or when treatment with Cabergoline should be reinstituted.
Child Dose
Renal Dose
Administration
Should be taken with food.
Contra Indications
Uncontrolled hypertension
Hypersensitivity to ergot derivatives
Severe hepatic disease
Concurrent use with D2 antagonists
History of pulmonary, pericardial, or retroperitoneal fibroti disorders
Women planning to nurse
History of cardiac valvular disorders as suggested by anatomical evidence of valvulopathy of any valve, determined by pretreatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis
Precautions
Initial doses >1 mg may produce orthostatic hypotension
Concomitant antihypertensives
May cause somnolence; avoid performing tasks that require mental alertness
Reportedly can cause cardiac damage
May cause orthostatic hypotension; avoid concurrent use with antihypertensives
Rare cases of retroperitoneal fibrosis reported
Hepatic impairment
Inhibits lactation
Impulse control/compulsive behaviors reported in patients receiving therapy; this has been generally reversible upon reduction of dose or treatment discontinuation; prescribers should consider dose reduction or stopping medication if a patient develops such urges while receiving therapy
Valvular disease
All patients should undergo a cardiovascular evaluation, including echocardiogram to assess the potential presence of valvular disease; if valvular disease is detected, the patient should not be treated with cabergoline
Following treatment initiation, clinical and diagnostic monitoring (for example, chest x-ray, CT scan and cardiac echocardiogram) should be conducted to assess the risk of cardiac valvulopathy
Discontinue if an echocardiogram reveals new valvular regurgitation, valvular restriction or valve leaflet thickening
Monitor for fibrotic disease.
Monitor blood pressure for a few days after starting treatment and following dosage increase.
Pregnancy-Lactation
Pregnancy Category: B
Lactation: excretion in milk unknown; not recommended
Interactions
Increased risk of orthostatic hypotension when used with antihypertensive.
May increase vasoconstriction effect of dopamine.
May reduce vasodilation effect of nitroglycerin.
Concurrent use with SSRIs or TCAs may increase the risk of serotonin syndrome.
Potentially Fatal: Risk of serotonin syndrome with sibutramine.
Contraindicated (14)
almotriptan
eletriptan
frovatriptan
glyceryl trinitrate pr
naratriptan
nitroglycerin IV
nitroglycerin sublingual
nitroglycerin topical
nitroglycerin transdermal
nitroglycerin translingual
rizatriptan
sumatriptan
sumatriptan intranasal
zolmitriptan
Adverse Effects
Side effects of Cabergoline :
>10%
Nausea (27%),Headache (26%),Dizziness (15%),Constipation (10%)
1-10%
Asthenia (9%),Fatigue (7%),Abdominal pain (5%),Somnolence (5%),Postural hypotension (4%),Depression (3%),Dyspepsia (2%),Nervousness (2%),Abnormal vision (1%),Breast pain (1%),Dysmenorrhea (1%),Hot flashes (1%),Paresthesia (1%)
Potentially Fatal: Risk of serotinin syndrome with sibutramine; avoid combination.
Mechanism of Action
Cabergoline is a long-acting dopamine D2-agonist. It inhibits prolactin secretion through hypothalamic inhibitory control exerted through the release of dopamine.
Note
Cabolin 1mg Tablet manufactured by Renata PLC.. Its generic name is Cabergoline. Cabolin is availble in Bangladesh.
Farmaco BD drug index information on Cabolin Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.